 Diagnosis of Williams syndrome |
| OF THE INVENTION The present invention is directed to the determination that SVAS and Williams ... |
|
| Biological material pre-fixation treatment |
| OF PREFERRED EMBODIMENTS In one aspect, the present invention relates to an improved bioprosthetic ... |
|
| Method for bonding or fusion of biological tissue and material |
| Biological materials are joined, repaired or fused by heating the material in proximity to a ... |
|
| Diagnosis and treatment of supravalvular aortic stenosis and Williams syndrome |
| OF THE INVENTION The present invention is directed to the determination that SVAS and Williams ... |
|
| Biological material pre-fixation treatment |
| OF PREFERRED EMBODIMENTS In one aspect, the present invention relates to an improved bioprosthetic ... |
|
| Matrix substrate for a viable body tissue-derived prosthesis and method for making the same |
| OF THE INVENTION The present invention covers a process that thoroughly removes intact cells from ... |
|
| Barrier webs having bioactive surfaces |
| What is claimed is: 1. A bioactive substrate comprising: a support; and a bioactive surface thereon,... |
|
| Biopolymer foams for use in tissue repair and reconstruction |
| OF THE INVENTION The present invention features biopolymer foams, composite biopolymer foams, ... |
|
| Periodate oxidative method for attachment of biomolecules to medical device surfaces |
| OF THE INVENTION As used in the specification and claims hereof, the following terms have the ... |
|
| Self-aligning peptides modeled on human elastin and other fibrous proteins |
| OF PREFERRED EMBODIMENTS The present invention is directed to unique polypeptides modeled on human ... |
|
|
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
| Details |
Inventors: Lode, Holger N.; Reisfeld, Ralph A.; Cheresh, David A.; Gillies, Stephen D.;
Assignee: The Scripps Research Institute (La Jolia, CA) EMD Lexigen Research Center Corp. (Billerica, MA)
Primary Examiner: Yu; Misook
Assistant Examiner:
Attorney, Agent or Firm: Olson & Hierl, Ltd.
The invention teaches methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response. |
|
DETAILED DESCRIPTION What is claimed is: 1.
A therapeutic composition comprising at least one angiogenesis inhibiting agent, which is an .
alpha.
.
sub.
v.
beta.
.
sub.
3 antagonist; and at least one anti-tumor immunotherapeutic agent, which is a fusion protein comprising cytokine IL-2 and an Ig heavy chain that immunoreacts with a tumor associated antigen target.
2.
A therapeutic composition of claim 1 comprising: a) an amount of at least one angiogenesis inhibiting agent sufficient to inhibit angiogenesis in a tumor or tumor metastases; and b) an amount of at least one anti-tumor immunotherapeutic agent sufficient to elicit a biological response.
3.
The composition of claim 1 wherein said .
alpha.
.
sub.
v.
beta.
.
sub.
3 antagonist is selected from the group consisting of a peptide, a RGD-containing peptide, an anti-.
alpha.
.
sub.
v.
beta.
.
sub.
3 monoclonal antibody, an anti-.
alpha.
.
sub.
v.
beta.
.
sub.
3 receptor monoclonal antibody, and an .
alpha.
.
sub.
v.
beta.
.
sub.
3 mimetic.
4.
The composition of claim 1 wherein said tumor associated antigen target is selected from the group consisting of AFP, CA 125, CEA, CD19, CD20, CD44, CD45, EGF Receptor, GD.
sub.
2, GD.
sub.
3, GM1, GM2, Her-2/Neu, Ep-CAM (KSA), IL-2 receptor, Lewis-Y, Lewis-X (CD 15), melanoma-associated proteoglycan MCSP, PSA and Transferrin Receptor.
5.
The composition of claim 1 wherein said anti-tumor immunotherapeutic agent is a fusion protein which comprises cytokine IL-2 and an Ig heavy chain that immunoreacts with the tumor associated antigen KSA (Ep-CAM, KS1/4 antigen).
6.
A kit for treating a tumor cell in a tumor or tumor metastases comprising a package comprising: a) an angiogenesis inhibiting agent, which is an .
alpha.
.
sub.
v.
beta.
.
sub.
3 antagonist capable of inhibiting angiogenesis in said tumor or said tumor metastases; b) an anti-tumor immunotherapeutic agent, which is a fusion protein comprising cytokine IL-2 and an Ig heavy chain that immunoreacts with the tumor associated antigen target; and c) instructions for using the agents in methods to treat tumors and tumor metastases
|
| Related patents |
|
|
Expressed sequence tags and encoded human proteins
The present invention relates to purified, isolated, or enriched 5' ESTs which include sequences derived from the authentic 5' ends of their corresponding mRNAs. The ...
|
|
|
C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
The invention claimed is: 1. An isolated PC-LECTIN protein comprising the amino acid sequence of SEQ ID NO. 2. 2. The PC-LECTIN protein of claim 1 which is soluble. 3. ...
|
|
|
Antibodies for use in determining hemoglobin A.sub.1c
It is accordingly an object of the present invention to provide a comparatively simple, inexpensive, reliable test for determining the long-term blood sugar level of a ...
|
|
|
Haptens, tracers, immunogens and antibodies for immunoassays for cotinine derivatives
OF THE INVENTION A hapten of the invention is substantially optically pure, and is particularly useful in an immunoassay for cotinine, a metabolite of nicotine. As used ...
|
|
|
Immunogens and the use thereof for obtaining antibodies against HBA.sub.1C
What is claimed is: 1. Composition of matter consisting essentially of polyclonal antibodies which specifically bind to HbA.sub.1c and which have less than 5.0% cross ...
|
|
|
Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
The present invention overcomes the above mentioned drawbacks and provides methods for treating drug abuse. Using therapeutic compositions, in particular hapten-carrier ...
|
|
|
Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay
OF THE INVENTION The present invention is directed to methods for developing and utilizing antibodies with preferred specificity for phenylboronic acid complexes of ...
|
|
|
Application of phytosterols (and their isomers), folic acid, cyanocobalamin and pyridoxin in dietetic (alimentary) fibers
The invention claimed is: 1. An oral pharmaceutical formulation comprising phytosterols and isomers thereof, folic acid, cyanocobalamine, pyridoxine and dietetic ...
|
|
|
Stimulation of chemotaxis by chemotactic peptides
Accordingly, it is an object of this invention to provide a synthetic material having chemotactic properties towards cells such as fibroblasts and endothelial cells. It ...
|
|
|
Biological material pre-fixation treatment
OF PREFERRED EMBODIMENTS In one aspect, the present invention relates to an improved bioprosthetic heart valve having an improved resistance to post-implantation ...
|
|
|
Drugs 
